BACKGROUND Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. OBJECTIVES This pre-specified analysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) determined whether polyvascular disease influenced risks of MACEs and death and their modification by alirocumab in patients with recent ACS and dyslipidemia despite intensive statin therapy.
P atients with peripheral artery disease (PAD) or cerebrovascular disease (CeVD) have an elevated risk of major adverse cardiovascular events (MACEs) and death compared with patients without these conditions, irrespective of a concurrent history of coronary artery disease (CAD) (1) (2) (3) . The risk of future MACEs and death also remains high among patients with an acute coronary syndrome (ACS), despite application of evidence-based secondary prevention measures including statins and dual antiplatelet therapy (4) .
When PAD or CeVD is concurrent with ACS, risk may be particularly elevated, warranting more intensive approaches to secondary prevention (5, 6) .
Lowering of atherogenic lipoproteins, reflected in part by reduction of low-density lipoprotein cholesterol (LDL-C), favorably modifies the risks of MACEs and death (7) . Accordingly, statin treatment is 
METHODS
Details of the study design (13) and primary efficacy and safety results have been published (14) . In Alirocumab and Polyvascular Disease in ODYSSEY OUTCOMES respectively. The corresponding ARR with alirocumab was 1.4% (95% CI: 0.6% to 2.3%), 1.9% (95% CI: À2.4% to 6.2%), and 13.0% (95% CI: À2.0% to 28.0%), with an interaction p ¼ 0.0006.
For all-cause death in ODYSSEY OUTCOMES, the overall incidence of death in the placebo and alirocumab groups was 4.1% and 3.5%, respectively, with a corresponding ARR of 0.6% (95% CI: 0.2% to 1.2%) (14) . Values are n/N (%) unless otherwise indicated. *HRs reflect stratification by geographic region in models with interaction between treatment and the 3 disease bed subgroups (monovascular disease, disease in 2 beds, and disease in 3 beds).
ARR ¼ absolute risk reduction; CAD ¼ coronary artery disease; CI ¼ confidence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiovascular event; other abbreviations as in Table 1 . Values are n (%) or n/N (%). *New-onset diabetes was defined according to the presence of 1 or more of the following, with confirmation of the diagnosis by blinded external review by experts in the field of diabetes: an adverse event report, a new prescription for diabetes medication, a glycated hemoglobin level of $6.5% on 2 occasions (and a baseline level of <6.5%), or a fasting serum glucose level of $126 mg/dl (7.0 mmol/l) on 2 occasions (and a baseline level of <126 mg/dl). Table 1 . Similar to MACEs, there was a gradient of absolute risk and ARR with alirocumab. In the placebo group, the incidence of death in patients with 1, 2, or 3 diseased vascular beds was 3.5%, 10.0%, and 21.8%, respectively. With alirocumab, the corresponding ARR was 0.4% (95% CI: À0.1% to 1.0%), 1.3% (95% CI: À1.8% to 4.3%), and 16.2% (95% CI: 5.5% to 26.8%), with an interaction p ¼ 0.002.
Abbreviations as in
Details of the primary MACE endpoint and allcause death are shown in Overall, there were no differences in the incidence of adverse events or laboratory abnormalities between alirocumab and placebo groups, with the exception of local injection-site reactions, which occurred more often in the alirocumab group (14) . KEY WORDS acute coronary syndrome, alirocumab, cerebrovascular disease, death, major adverse cardiac events, peripheral artery disease APPENDIX For supplemental tables and a complete list of the ODYSSEY OUTCOMES committees and investigators, please see the online version of this paper.
